½ÃÀ庸°í¼­
»óǰÄÚµå
1290602

¼¼°èÀÇ ÇÇÇÏ ¾à¹°Àü´Þ ½ÃÀå : »ç¿ë¼ºº°, ÀûÀÀÁõº°(ÀÚ°¡¸é¿ªÁúȯ, ½Å°æÁúȯ, Á¾¾çÁúȯ, È£¸£¸óÁúȯ, ±âŸ), Àü´Þ½Ã½ºÅÛº°, Áö¿ªº° - ±Ô¸ð, Á¡À¯À², Àü¸Á, ±âȸ ºÐ¼®(2023-2030³â)

Subcutaneous Drug Delivery Market, By Usability, Disease Indication(Auto-immune Disorders, Neurological Disorders, Oncology Disorders, Hormonal Disorders, & Others), Delivery System, & Region-Size, Share, Outlook, & Opportunity Analysis, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÇÁ¸®ÇÊµå ½Ã¸°Áö ¹× ÀÚµ¿ ÁÖ»ç±âÀÇ Çõ½Å°ú °³Ã´ÀÌ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, µ¶ÀÏÀÇ 1Â÷ Æ÷Àå Á¦Á¶¾÷üÀÎ Gerresheimer´Â 2020³â 6¿ù¿¡ ÅÖ½ºÅÙÀ» »ç¿ëÇÏÁö ¾Ê°í ±Ý¼Ó ¿À¿° °¡´É¼ºÀ» ÀÌ»óÀûÀ¸·Î Á¦°ÅÇÑ »ý¸í°øÇÐ ±â¼ú·Î Á¦Á¶µÈ À¯È¿ ¼ººÐÀ» À§ÇÑ ¿Ïº®ÇÑ 1Â÷ Æ÷ÀåÀç 'Lure Lock Gx RTF Syringe'¸¦ Ãâ½ÃÇß½À´Ï´Ù.

¶ÇÇÑ 2022³â 3¿ù, ÀÇ·á±â±â Á¦Á¶¾÷üÀÎ YpsoMed´Â YpsoMate SmartPilotÀ» °³¹ßÇÏ¿© YpsoMate Ææ¿¡ Àç»ç¿ë °¡´ÉÇÑ ºÎÂø¹°·Î 2´Ü°è ÁÖ»ç °úÁ¤À» ½±°Ô ÇÒ ¼ö ÀÖ´Â YpsoMate SmartPilotÀ» °³¹ßÇß½À´Ï´Ù. ÀÌ ÀåÄ¡¿¡´Â ¼¾¼­¿Í ¸Þ¸ð¸®°¡ ÀåÂøµÇ¾î ÀÖÀ¸¸ç, ¾Û°ú ¿¬°áÇÏ¿© ÁÖ»ç ŸÀְ̹ú ¿ë·®À» Ç¥½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù. ÆæÀº »ç¿ëÀÚ¿¡°Ô À½¼º ¹× ½Ã°¢Àû Çǵå¹éÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ¾ÛÀº »ç¿ëÀÚ¿¡°Ô Àν¶¸° ÁÖÀÔ ½Ã±â¸¦ ¾Ë·ÁÁÙ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

±ÔÁ¦ ´ç±¹ÀÇ Á¦Ç° ½ÂÀÎÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 3¿ù 6ÀÏ, ¼¼°è ¹ÙÀÌ¿À½Ã¹Ð·¯ ±â¾÷ÀÎ Coherus BioSciences, Inc´Â ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÌ UDENYCA(pegfilgrastim-cbqv) ´ÜÀÏ ¿ë·®, »çÀü ÃæÀü½Ä ÀÚµ¿ ÁÖÀÔ±âÀÇ ¹ßÇ¥¸¦ ½ÂÀÎÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. UDENYCA ÀÚµ¿ÁÖ»ç±â´Â »ç¹«½Ç°ú °¡Á¤¿¡¼­ ¸ðµÎ »ç¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÕ¸®ÀûÀÌ°í »ç¿ëÇϱ⠽¬¿î µðÀÚÀÎÀ¸·Î ¼³°èµÇ¾ú½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ÀÌ º¸°í¼­´Â ¼¼°è ÇÇÇÏ ¾à¹°Àü´Þ ½ÃÀåÀ» ÀÚ¼¼È÷ ºÐ¼®Çϰí 2022³âÀ» ±âÁØ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2023-2030³â) ½ÃÀå ±Ô¸ð¿Í CAGRÀ» Á¦°øÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®ÀÇ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ÆÄ¾ÇÇϰí ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¶Ç´Â ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ª Àü¸Á ¹× ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÑ °æÀï Àü·«¿¡ ´ëÇÑ Áß¿äÇÑ °í·Á »çÇ×À» Á¦°øÇÕ´Ï´Ù.
  • ±â¾÷ °³¿ä, ½ÇÀû, Á¦Ç° Æ÷Æ®Æú¸®¿À, ½ÃÀå ÀÔÁö, À¯Åë Àü·«, ÁÖ¿ä °³¹ß, Àü·« ¹× ÇâÈÄ °èȹ°ú °°Àº ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ÇÇÇÏ ¾à¹°Àü´Þ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.
  • Á¶»ç ´ë»ó ÁÖ¿ä ±â¾÷À¸·Î´Â Becton Dickinson and Company, Novo Nordisk A/S, Johnson & Johnson, Johnson, Novartis International AG, Amgen, Inc. Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Consort Medical plc, Eli Lilly and Company, Merck & Co. Pharmaceutical Services, Inc Gerresheimer AG µîÀÌ ÀÖ½À´Ï´Ù.
  • ÀÌ º¸°í¼­¿¡¼­ ¾òÀº ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷ÀÇ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í °ü¸® ´ç±¹Àº ÇâÈÄ Á¦Ç° Ãâ½Ã, ±â¼ú °³¼±, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ÇÇÇÏ ¾à¹°Àü´Þ ¼¼°è ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°è ÇÇÇÏ ¾à¹°Àü´Þ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ °³¿ä
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
    • ½ÃÀå ÇöȲ : »ç¿ë¼ºº°
    • ½ÃÀå ÇöȲ : ÀûÀÀ Áúȯº°
    • ½ÃÀå ÇöȲ : µô¸®¹ö¸® ½Ã½ºÅÛº°
    • ½ÃÀå ÇöȲ : À¯Åë ä³Îº°
    • ½ÃÀå ÇöȲ : Áö¿ªº°
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¿µÇ⠺м®
  • ÃÖ±ÙÀÇ Á¦Ç° ¹ßÇ¥
  • ÇÕº´, Àμö, °øµ¿ ¿¬±¸
  • Á¦Ç° ¹ß¸Å
  • ¹ý±ÔÁ¦ ½Ã³ª¸®¿À
  • PEST ºÐ¼®

Á¦4Àå ¼¼°èÀÇ ÇÇÇÏ ¾à¹°Àü´Þ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • °æÁ¦Àû ¿µÇâ
  • COVID-19 ¿ªÇÐ
  • ¼ö¿ä ¹× °ø±Þ¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ÇÇÇÏ ¾à¹°Àü´Þ ½ÃÀå : À¯Àúºô¸®Æ¼º°, 2017-2030³â

  • ÀÏȸ¿ë
  • ÀçÀÌ¿ë °¡´É

Á¦6Àå ¼¼°èÀÇ ÇÇÇÏ ¾à¹°Àü´Þ ½ÃÀå : ÀûÀÀ Áúȯº°, 2017³â-2030³â

  • ÀÚ°¡¸é¿ª Áúȯ
  • ½Å°æ°è Áúȯ
  • Á¾¾ç Áúȯ
  • È£¸£¸ó Áúȯ
  • ¾Ë·¹¸£±â ¹× °¨¿°Áõ
  • ¾È°ú Áúȯ
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ ÇÇÇÏ ¾à¹°Àü´Þ ½ÃÀå : µô¸®¹ö¸® ½Ã½ºÅÛº°, 2017³â-2030³â

  • ÇÁ¸®ÇÊµå ½Ã¸°Áö
  • ÀÚ°¡ÁÖ»ç±â
  • ÆæÇü ÀÎÁ§ÅÍ
  • ÀÏȸ¿ë
  • ±âŸ(ÆßÇÁ µî)

Á¦8Àå ¼¼°èÀÇ ÇÇÇÏ ¾à¹°Àü´Þ ½ÃÀå : À¯Åë ä³Îº°, 2017³â-2030³â

  • º´¿ø³» ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦9Àå ¼¼°èÀÇ ÇÇÇÏ ¾à¹°Àü´Þ ½ÃÀå : Áö¿ªº°, 2017³â-2030³â

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • ASEAN
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ Áö¿ª
  • GCC ±¹°¡
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹

Á¦10Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • Becton Dickinson and Company
    • Novo Nordisk A/S
    • Johnson & Johnson.
    • Novartis International AG
    • Amgen, Inc
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche AG.
    • Consort Medical plc.
    • LaVision Biotec GmbH
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Insulet Corporation
    • West Pharmaceutical Services, Inc.
    • Gerresheimer AG.

Á¦11Àå ¼½¼Ç

  • Âü°í ¹®Çå
  • Á¶»ç ¹æ¹ý
lsh 23.06.30

Technological innovations and developments in prefilled syringes and auto-injectors is contributing to the market growth. For instance, Gerresheimer, German manufacturer of primary packaging introduced metal-free Lure Lock Gx RTF Syringe in June 2020, without tungsten to create the perfect primary packaging material for biotechnologically manufactured active ingredients that ideally exclude the possibility of contamination with metal.

Moreover, in March 2022, YpsoMed, medical device companies developed YpsoMate SmartPilot, a reusable attachment to its proprietary YpsoMate pen, which is designed for an easy two-step injection process. The device has a sensor and memory, which is connected to an app, which displays injection timing and doses. The pen provides audio and visual feedback to users. The app can also remind users when it is time to inject the insulin.

Market Dynamics

Product approvals by regulatory authorities is expected to drive the market growth over the forecast period. For instance, on March 6, 2023, Coherus BioSciences, Inc, its global biosimilar company, announced U.S. Food and Drug Administration (FDA) approved a single-dose, prefilled auto injector presentation of UDENYCA (pegfilgrastim-cbqv). The UDENYCA autoinjector has a streamlined, easy-to-use design for use in both in-office and at-home settings of care.

Key features of the study:

  • This report provides in-depth analysis of the global subcutaneous drug delivery market and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global subcutaneous drug delivery market based on the following parameters-company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Becton Dickinson and Company, Novo Nordisk A/S, Johnson & Johnson, Inc., Novartis International AG, Amgen, Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Consort Medical plc, Eli Lilly and Company, Merck & Co., Inc., Insulet Corporation, West Pharmaceutical Services, Inc Gerresheimer AG and other prominent key players.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • Global subcutaneous drug delivery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global subcutaneous drug delivery market

Detailed Segmentation:

  • Global Subcutaneous Drug Delivery Market, Usability
    • Disposable
    • Reusable
  • Global Subcutaneous Drug Delivery Market, Disease Indication
    • Auto-immune Disorders
    • Neurological Disorders
    • Oncology Disorders
    • Hormonal Disorders
    • Allergy & Infectious Disorders
    • Ophthalmic Disorders
    • Others
  • Global Subcutaneous Drug Delivery Market, Delivery System
    • Prefilled Syringes
    • Autoinjector
      • Spring Type
      • Motorized Type
      • Wearable Type
    • Pen Injectors
      • Disposable
      • Reusable
      • Syringes (Injector)
    • Others (pump, etc.)
  • Global Subcutaneous Drug Delivery Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Subcutaneous Drug Delivery Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country:
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Becton Dickinson and Company,
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Novo Nordisk A/S,
    • Johnson & Johnson
    • Novartis International AG
    • Amgen, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche AG.,
    • Consort Medical plc,
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Insulet Corporation,
    • West Pharmaceutical Services, Inc.
    • Gerresheimer AG

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Usability
    • Market Snapshot, By Disease Indication
    • Market Snapshot, By Delivery System
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Recent Product Launches
  • Merger, Acquisition, and Collaborations
  • Product Launch
  • Regulatory Scenario
  • PEST Analysis

4. Global Subcutaneous Drug Delivery Market- Impact of Coronavirus (Covid-19) Pandemic

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Subcutaneous Drug Delivery Market, By Usability, 2017-2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Disposable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Reusable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

6. Global Subcutaneous Drug Delivery Market, By Disease Indication , 2017-2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Auto-immune Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Neurological Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Oncology Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Hormonal Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Allergy & Infectious Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Ophthalmic Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

7. Global Subcutaneous Drug Delivery Market, By Delivery System, 2017-2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Prefilled Syringes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Auto injector
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Pen Injectors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Disposable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Others (pump, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

8. Global Subcutaneous Drug Delivery Market, By Distribution Channel, 2017-2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

9. Global Subcutaneous Drug Delivery Market, By Region, 2017-2030, (US$ Billion)

  • Overview
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Usability , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Delivery System , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017- 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017- 2030, (US$ Billion)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Usability , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Delivery System , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017- 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017- 2030, (US$ Billion)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Usability , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Delivery System , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017- 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017- 2030, (US$ Billion)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Usability , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Delivery System , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017- 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017- 2030, (US$ Billion)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Usability , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Delivery System , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017- 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017- 2030, (US$ Billion)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Usability , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Delivery System , 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017- 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017- 2030, (US$ Billion)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Company Profiles
    • Becton Dickinson and Company
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Novo Nordisk A/S
    • Johnson & Johnson.
    • Novartis International AG
    • Amgen, Inc
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche AG.
    • Consort Medical plc.
    • LaVision Biotec GmbH
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Insulet Corporation
    • West Pharmaceutical Services, Inc.
    • Gerresheimer AG.

11. Section

  • References
  • Research Methodology
  • About us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦